Skip to main content

Supportive Care in Cancer

Ausgabe 10/2011

Inhalt (24 Artikel)

Open Access Original Article

Development of the Psychosocial Distress Questionnaire—Breast Cancer (PDQ-BC): a breast cancer-specific screening instrument for psychosocial problems

Mirjam P. J. Bogaarts, Brenda L. Den Oudsten, Jan A. Roukema, Johanna M. G. H. Van Riel, Laurens V. Beerepoot, Jolanda De Vries

Open Access Original Article

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)

Nicola Di Renzo, Antonella Montanini, Donato Mannina, Alessandra Dondi, Stefania Muci, Salvatrice Mancuso, M. Rosaria De Paolis, Caterina Plati, Caterina Stelitano, Catia Patti, Attilio Olivieri, Eliana Liardo, Gabriele Buda, Renato Cantaffa, Massimo Federico

Original Article

The relationship between weight loss and health-related quality of life in persons treated for head and neck cancer

Barbara A. Head, Luke Heitz, Cynthia Keeney, John Myers, Savitri N. Appana, Jamie L. Studts, Jeffrey Bumpous, Mark Pfeifer

Original Article

Quality of life and mental health in family caregivers of patients with terminal cancer

Jong Im Song, Dong Wook Shin, Jin Young Choi, Jina Kang, Young Ji Baik, Hana Mo, Myung Hee Park, Sung Eun Choi, Jeong Ho Kwak, Eun Jin Kim

Original Article

Small increases in serum creatinine are associated with prolonged ICU stay and increased hospital mortality in critically ill patients with cancer

Joshua Samuels, Chaan S. Ng, Joseph Nates, Kristen Price, Kevin Finkel, Abdulla Salahudeen, Andrew Shaw

Original Article

Anticipatory nausea and vomiting

Joseph A. Roscoe, Gary R. Morrow, Matti S. Aapro, Alexander Molassiotis, Ian Olver

Original Article

Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study

Carlo Pirri, Paul Katris, James Trotter, Evan Bayliss, Robert Bennett, Peter Drummond

Original Article

European French-speaking study from the GEMO group on bone metastases management: a special focus on external beam radiotherapy practice survey

Nicolas Magné, Cyrus Chargari, René Olivier Mirimanoff, Pierre Olivier, Jean Philippe Vuillez, Michèle Tubiana-Hulin, Jean Jacques Body, Jean Léon Lagrange

Original Article

No impact of central venous insertion site on oncology patients’ quality of life and psychological distress. A randomized three-arm trial

Roberto Biffi, Franco Orsi, Simonetta Pozzi, Andrea Maldifassi, Davide Radice, Nicole Rotmensz, Maria Giulia Zampino, Nicola Fazio, Giulia Peruzzotti, Florence Didier

Open Access Original Article

Factors predicting clinically significant fatigue in women following treatment for primary breast cancer

Lynn H. Gerber, Nicole Stout, Charles McGarvey, Peter Soballe, Ching-yi Shieh, Guoqing Diao, Barbara A. Springer, Lucinda A. Pfalzer

Open Access Original Article

The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia

Karin G. E. Miedema, Eveline S. J. M. de Bont, Rob F. M. Oude Elferink, Michel J. van Vliet, Claudi S. M. Oude Nijhuis, Willem A. Kamps, Wim J. E. Tissing

Original Article

Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)

Aminah Jatoi, Shaker R. Dakhil, Jeff A. Sloan, John W. Kugler, Kendrith M. Rowland Jr., Paul L. Schaefer, Paul J. Novotny, Donald B. Wender, Howard M. Gross, Charles L. Loprinzi

Original Article

Myeloid growth factor therapy in malignant lymphomas—a 5-year retrospective study from Hungary

László Váróczy, Lajos Gergely, Edit Páyer, Zsófia Miltényi, Zsófia Simon, Árpád Illés

Original Article

Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network

Edwin Pun Hui, Linda K. S. Leung, Terence C. W. Poon, Frankie Mo, Vicky T. C. Chan, Ada T. W. Ma, Annette Poon, Eugenie K. Hui, So-shan Mak, Maria Lai, Kenny I. K. Lei, Brigette B. Y. Ma, Tony S. K. Mok, Winnie Yeo, Benny C. Y. Zee, Anthony T. C. Chan

Open Access Original Article

Explorative study on the aftercare of pediatric brain tumor survivors: a parents’ perspective

Eline J. Aukema, Bob F. Last, A. Y. Netteke Schouten-van Meeteren, Martha A. Grootenhuis

Original Article

A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients

Catherine E. Jansen, Bruce A. Cooper, Marylin J. Dodd, Christine A. Miaskowski

Original Article

Medical cost analysis for antifungal prophylaxis in neutropenic patients with hematological malignancies: a systematic simulation analysis

Osamu Imataki, Yoshitsugu Kubota, Hiroaki Ohnishi, Akira Kitanaka, Toshihiko Ishida, Terukazu Tanaka

Open Access Original Article

Malnutrition in patients treated for oral or oropharyngeal cancer—prevalence and relationship with oral symptoms: an explorative study

Harriët Jager-Wittenaar, Pieter U. Dijkstra, Arjan Vissink, Rob P. van Oort, Bernard F. A. M. van der Laan, Jan L. N. Roodenburg

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.